The CLL Research Consortium (CRC) is multi-institutional research program with a mission to develop improved and potentially curative treatments for patients with chronic lymphocytic leukemia (CLL). The CRC provides an infrastructure that facilitates research on novel therapies and on clinical-laboratory relationships that improve clinical staging and/or assist in the early assessment of response to therapy. The CRC has six projects. Proj, 1 (Croce) investigates the genetic basis for CLL and examines the expression and function of non-coding RNA found to influence pathogenesis and disease progression. Proj, 2 (Reed) examines novel chemical antagonists that target proteins that inhibit apoptosis. Proj, 3 (Kipps) examines strategies for active immune therapy, factors involved in the cross talk in the CLL-cell microenvironment, and novel approaches to target R0R1, a leukemia-associated antigen. Proj. 4 (Gribben) evaluates T cell defects that impair cognate intercellular interactions and/or development of effective anti-tumor immunity and investigates strategies for allogeneic stem cell transplantation. Proj. 5 (Plunkett) examines the activity of promising anticancer agents alone or in mechanism-based combinations. Proj. 6 (Grever) studies inhibitors of key metabolic pathways implicated in pathogenesis and/or disease progression. The CRC has 4 cores: Core A (Kipps) provides scientific and administrative oversight, organizes meetings, facilitates communication, monitors for compliance with regulatory agencies, and provides biomedical informatics and data management. Core B (Neuberg) assists in the design, implementation, and data analyses of basic and clinical research projects. Core C (Rassenti) provides for tissue banking, sample trafficking, and sample validation. It ensures uniform analyses of genetic and phenotypic features of stored samples, processes samples from patients treated on CRC clinical studies, and ensures appropriate access to samples for correlative science studies and hypothesis-testing research. Core D (Wierda) facilitates development and execution of clinical trials, identifies new strategies for treatment, facilitates correlative laboratory studies, and assesses laboratory and clinical parameters collected on patients participating in CRC clinical studies.
This program is studying chronic lymphocytic leukemia (CLL), the most common adult leukemia in the U.S. Research projects on genetics and biology of CLL are integrated in an infrastructure that facilitates discovery and initial validation of novel approaches to treat patients with this incurable disease. Success in these efforts is anticipated to have major implications to our understanding and treatment of cancer in general.
|Mani, R; Mao, Y; Frissora, F W et al. (2015) Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia 29:346-55|
|Veronese, A; Pepe, F; Chiacchia, J et al. (2015) Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia 29:86-95|
|Woyach, Jennifer A; Furman, Richard R; Liu, Ta-Ming et al. (2014) Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286-94|
|Chen, Wenbing; Han, Yanyan; Peng, Xiaohua (2014) Aromatic nitrogen mustard-based prodrugs: activity, selectivity, and the mechanism of DNA cross-linking. Chemistry 20:7410-8|
|Stephens, D M; Ruppert, A S; Jones, J A et al. (2014) Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia 28:1365-8|
|Cheney, Carolyn M; Stephens, Deborah M; Mo, Xiaokui et al. (2014) Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs 6:749-55|
|Strati, Paolo; Ferrajoli, Alessandra; Lerner, Susan et al. (2014) Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma 55:828-33|
|Cui, Bing; Chen, Liguang; Zhang, Suping et al. (2014) MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 124:546-54|
|Riches, John C; Gribben, John G (2014) Hanging tough: CMV-specific CD8+ T cells in CLL. Blood 123:608-9|
|Fecteau, Jessie-F; Corral, Laura G; Ghia, Emanuela M et al. (2014) Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood 124:1637-44|
Showing the most recent 10 out of 227 publications